Literature DB >> 1084352

The effects of epinephrine infusion in patients with von Willebrand's disease.

F R Rickles, L W Hoyer, M E Rick, D J Ahr.   

Abstract

Epinephrine infusion causes variable increases in the components of the Factor VIII (antihemophilic factor) complex in patients with von Willebrand's disease. The increase in antihemophilic factor procoagulant activity was greater than that of Factor VIII-related antigen and von Willebrand factor activity in two patients with von Willebrand's disease. Similar increases in the three individual factors were demonstrated in two other patients. A 4-10-fold increase in Factor VIII-related properties was identified in each of these individuals after infusion. One patient has been studied with very severe von Willebrand's disease; none of the Factor VIII-related properties increased despite two infusions of epinephrine. Bleeding times were normalized or remained normal in the two patients whose von Willebrand factor activity was greater than 25 U/100 ml. It remained prolonged in those three patients whose von Willebrand factor activity levels remained below that concentration. The increase in procoagulant activity was transient in all patients and t 1/2 values were estimated to be between 0.8 and 3.4 h.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1084352      PMCID: PMC436821          DOI: 10.1172/JCI108432

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  STUDIES OF THE ANTIHEMOPHILIC FACTOR (AHF, FACTOR VIII) PRODUCED IN VON WILLEBRAND'S DISEASE.

Authors:  E M BARROW; H R ROBERTS; K PONS; J B GRAHAM
Journal:  Proc Soc Exp Biol Med       Date:  1964-03

2.  CHANGES IN THE ACTIVITY OF ANTIHEMOPHILIC A FACTOR (F. VIII) AND IN THE BLEEDING TIME ASSOCIATED WITH MUSCULAR EXERCISE AND ADRENALIN INFUSION.

Authors:  O EGEBERG
Journal:  Scand J Clin Lab Invest       Date:  1963       Impact factor: 1.713

3.  MEASUREMENT OF PLATELET ADHESIVENESS. A SIMPLE IN VITRO TECHNIQUE DEMONSTRATING AN ABNORMALITY IN VON WILLEBRAND'S DISEASE.

Authors:  E W SALZMAN
Journal:  J Lab Clin Med       Date:  1963-11

4.  Transfusion studies in von Willebrand's disease: effect on bleeding time and factor VIII.

Authors:  P CORNU; M J LARRIEU; J CAEN; J BERNARD
Journal:  Br J Haematol       Date:  1963-04       Impact factor: 6.998

5.  The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity.

Authors:  S I RAPAPORT; S SCHIFFMAN; M J PATCH; S B AMES
Journal:  Blood       Date:  1963-02       Impact factor: 22.113

6.  The treatment of haemorrhage in von Willebrand's disease and the blood level of factor VIII (AHG).

Authors:  R BIGGS; J M MATTHEWS
Journal:  Br J Haematol       Date:  1963-04       Impact factor: 6.998

7.  Studies on the nature of the circulating anticoagulant directed against antihemophilic factor: with notes on an assay for anthemophilic factor.

Authors:  R T BRECKENRIDGE; C D RATNOFF
Journal:  Blood       Date:  1962-08       Impact factor: 22.113

8.  Increase in antihaemophilic globulin activity following infusion of adrenaline.

Authors:  G I INGRAM
Journal:  J Physiol       Date:  1961-04       Impact factor: 5.182

9.  The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies.

Authors:  R R PROCTOR; S I RAPAPORT
Journal:  Am J Clin Pathol       Date:  1961-09       Impact factor: 2.493

10.  v. Willebrand's disease in Sweden; its pathogenesis and treatment.

Authors:  I M NILSSON; M BLOMBACK; B BLOMBACK
Journal:  Acta Med Scand       Date:  1959-06-30
View more
  12 in total

1.  The properties of immune complexes formed by human antibodies to factor VIII.

Authors:  J Lazarchick; L W Hoyer
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

Review 2.  Functional architecture of Weibel-Palade bodies.

Authors:  Karine M Valentijn; J Evan Sadler; Jack A Valentijn; Jan Voorberg; Jeroen Eikenboom
Journal:  Blood       Date:  2011-01-25       Impact factor: 22.113

3.  Endothelial Von Willebrand factor promotes blood-brain barrier flexibility and provides protection from hypoxia and seizures in mice.

Authors:  Georgette L Suidan; Alexander Brill; Simon F De Meyer; Jaymie R Voorhees; Stephen M Cifuni; Jessica E Cabral; Denisa D Wagner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-07-03       Impact factor: 8.311

4.  Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.

Authors:  H J Weiss; I I Sussman; L W Hoyer
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

5.  A novel modifier gene for plasma von Willebrand factor level maps to distal mouse chromosome 11.

Authors:  K L Mohlke; W C Nichols; R J Westrick; E K Novak; K A Cooney; R T Swank; D Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

6.  Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.

Authors:  J E Kaufmann; A Oksche; C B Wollheim; G Günther; W Rosenthal; U M Vischer
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

7.  Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A.

Authors:  Qizhen Shi; Scot A Fahs; Erin L Kuether; Brian C Cooley; Hartmut Weiler; Robert R Montgomery
Journal:  Blood       Date:  2010-07-06       Impact factor: 22.113

8.  The Epac-Rap1 signaling pathway controls cAMP-mediated exocytosis of Weibel-Palade bodies in endothelial cells.

Authors:  Kathinka W E M van Hooren; Ellen L van Agtmaal; Mar Fernandez-Borja; Jan A van Mourik; Jan Voorberg; Ruben Bierings
Journal:  J Biol Chem       Date:  2012-04-16       Impact factor: 5.157

9.  Fluvastatin inhibits regulated secretion of endothelial cell von Willebrand factor in response to diverse secretagogues.

Authors:  Richard J Fish; Hong Yang; Christelle Viglino; Raoul Schorer; Sylvie Dunoyer-Geindre; Egbert K O Kruithof
Journal:  Biochem J       Date:  2007-08-01       Impact factor: 3.857

Review 10.  VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.

Authors:  Michael Schwameis; Christian Schörgenhofer; Alice Assinger; Margarete M Steiner; Bernd Jilma
Journal:  Thromb Haemost       Date:  2014-12-11       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.